Streetbeat News

Earnings

ICD

Independence Contract (NYSE:ICD) is scheduled to release its quarterly earnings report on February 28, 2024, with an estimated EPS of $-0.28. Analysts and investors will be closely watching for any positive guidance for the next quarter, especially considering the company's mixed historical earnings performance and the significant 53.23% decline in its share price over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 8:01 pm

CLMB

Climb Global Solutions (NASDAQ:CLMB) is scheduled to release its quarterly earnings report on February 28, 2024, with an estimated EPS of $0.68. Historical data shows mixed reactions to past earnings, with a notable 2.8% drop after a miss last quarter. Shares have risen 51.81% over the past year, indicating positive sentiment among long-term investors.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 8:01 pm

VST

Vistra (NYSE:VST) is scheduled to release its quarterly earnings report on February 28, 2024, with an expected EPS of $0.26. Analysts and investors are keen on whether Vistra will surpass this estimate and provide positive guidance for the next quarter. Historical data shows mixed earnings performance, with a notable miss last quarter leading to a slight share price drop. Vistra's stock has seen a significant increase of 131.64% over the last 52 weeks, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 8:01 pm

DAKT

Daktronics (NASDAQ:DAKT) is scheduled to release its quarterly earnings report on February 28, 2024, with an estimated EPS of $0.17. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Daktronics's past earnings performance shows a mix of beats and misses, with the stock price reacting variably. The company's shares have seen a significant increase of 102.83% over the last 52 weeks, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 8:00 pm

PRGO

Perrigo Company plc (NYSE:PRGO) reported mixed Q4 earnings with a slight miss on net sales at $1.16 billion versus the consensus of $1.18 billion but beat EPS estimates with $0.86, up 14.7% Y/Y. The company announced Project Energize, a cost-saving plan expected to yield $140-$170 million in annual pre-tax savings by 2026, despite projecting a net reduction of 6% of its workforce. Perrigo forecasts FY 2024 organic net sales growth of 1.0%-3.0% and adjusted EPS of $2.50-$2.65, below the consensus of $3.00. PRGO shares dropped 15.3% to $27.25.

Portfolio Pulse from Vandana Singh

February 27, 2024 | 7:46 pm

TMDX

TransMedics Group Inc (NASDAQ:TMDX) reported a Q4 profit with revenue of $81.2 million, up 159% Y/Y, surpassing the consensus of $68.51 million. The growth was attributed to increased use of its Organ Care System (OCS) and new logistics services. EPS was $0.12, beating the expected loss of $(0.03). The company expects FY 2024 revenues of $360-$370 million, above the consensus of $330.23 million. Oppenheimer raised TMDX's price target from $92 to $105 with an Outperform rating, and William Blair maintains an Outperform rating, highlighting the company's strong Q4 results and promising outlook.

Portfolio Pulse from Vandana Singh

February 27, 2024 | 7:33 pm

HIMS

JANX

NERV

NRXP

SJM

TWKS

VKTX

U.S. stocks showed mixed performance with the Dow Jones falling by 0.35% and the NASDAQ rising by 0.28%. J.M. Smucker reported better-than-expected earnings, while Janux Therapeutics, Hims & Hers Health, and Viking Therapeutics saw significant stock price increases. Conversely, Minerva Neurosciences, Thoughtworks Holding, and NRx Pharmaceuticals experienced notable declines. Oil and gold prices saw slight increases.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 7:32 pm

CMCSA

PARA

WBD

Warner Bros. Discovery Inc (NASDAQ:WBD) has ended talks about acquiring Paramount Global (NASDAQ:PARA), causing both stocks to rise. Despite this, Paramount is still exploring sale options, with Skydance Media conducting due diligence and Byron Allen offering $14 billion. Comcast Corp (NASDAQ:CMCSA) is focusing on potential collaborations rather than acquisition. Both WBD and PARA face challenges, with WBD's shares dropping 10% after disappointing earnings and PARA trading near a 52-week low. WBD has lost 25.3% YTD, and PARA 22%.

Portfolio Pulse from Anusuya Lahiri

February 27, 2024 | 7:19 pm

DIA

IWM

JANX

QQQ

SPY

VKTX

XLU

On Tuesday, the S&P 500 and Nasdaq 100 saw declines, while small caps and certain biotech stocks experienced significant gains. The iShares Russell 2000 ETF (IWM) rose over 1%, marking its fourth consecutive session of gains. Durable goods orders fell more than expected, and oil prices reached their highest close since mid-November 2023. Bitcoin surged over 4%, reaching its highest level since December 2021. Major ETFs like SPY, DIA, and QQQ saw slight declines, while XLU outperformed. Biotech stocks Viking Therapeutics and Janux Therapeutics saw dramatic increases following positive trial results. Other notable stock movements included gains for Norwegian Cruise Line and Lowe's, and declines for Clarivate and American Tower.

Portfolio Pulse from Piero Cingari

February 27, 2024 | 7:18 pm

DHR

VLTO

BMO Capital Markets analyst John P. McNulty initiated coverage on Veralto Corporation (VLTO) with an Outperform rating and a price target of $97, citing strong EPS growth potential in the next 2-3 years. Veralto, which spun off from Danaher Corp (DHR) and began NYSE trading in October 2023, is expected to leverage its high-margin businesses and significant free cash flow for M&A to support double-digit EPS growth. The company recently reported Q4 earnings that beat consensus estimates and anticipates flat Y/Y non-GAAP core sales for Q1 FY24 with adjusted EPS of $0.73-$0.78.

Portfolio Pulse from Lekha Gupta

February 27, 2024 | 7:15 pm